← Human Trials & Peer-Reviewed Studies
A randomized control trial to assess the impact of vitamin D supplementation compared to placebo on vascular stiffness in chronic kidney disease patients.
Plain-language guide to PMID 25381032 (2014): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.
Key Facts
- PMID
- 25381032
- Journal
- BMC cardiovascular disorders
- Year
- 2014
- Study type
- Randomized Controlled Trial
- Authors
- Levin A et al. (7 authors)
- DOI
- 10.1186/1471-2261-14-156
- Registered trial
- NCT01247311
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.
The active form of the hormone (1,25 OH2D3) binds to receptors in multiple organs.
CKD patients are deficient in both 25 Vitamin D and 1,25 OH2D3.
Who Took Part
Other measurements include BP, kidney function and serial blood levels of biomarkers.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.
For those already receiving vitamin D therapies, a 3 month washout period before randomization is mandatory.
The primary outcome measure is Vascular stiffness, measured non-invasively by pulse wave velocity (PWV).
The primary analysis will compare any vitamin D therapy versus placebo for the primary outcome defined as the change of PWV from baseline to 6 months.
What Was Measured
PubMed files the paper under topics including British Columbia, Calcifediol, Calcitriol, Cardiovascular Diseases, Clinical Protocols, Dietary Supplements and Glomerular Filtration Rate.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.
The abstract goes on to report its results in about 2 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2014 (BMC cardiovascular disorders), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.